Brain Atrophy Is Associated with Disability Progression in Patients with MS followed in a Clinical Routine
暂无分享,去创建一个
D. Ramasamy | M. Dwyer | R. Zivadinov | B. Weinstock-Guttman | J. Hagemeier | D. Jakimovski | N. Bergsland | E. Carl | D. Hojnacki | C. Kolb | M. Dwyer | D. Silva | I. Paunkoski | E. Ghione | Ivo Paunkoski
[1] M. Dwyer,et al. Establishing pathological cut-offs for lateral ventricular volume expansion rates , 2018, NeuroImage: Clinical.
[2] Robert Zivadinov,et al. Assessing ‘No Evidence of Disease Activity’ Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study , 2017, CNS Drugs.
[3] M. Dwyer,et al. Feasibility of Brain Atrophy Measurement in Clinical Routine without Prior Standardization of the MRI Protocol: Results from MS-MRIUS, a Longitudinal Observational, Multicenter Real-World Outcome Study in Patients with Relapsing-Remitting MS , 2017, American Journal of Neuroradiology.
[4] L. Kappos,et al. Teriflunomide slows BVL in relapsing MS , 2017, Neurology: Neuroimmunology & Neuroinflammation.
[5] D. Ramasamy,et al. Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis , 2017, NeuroImage: Clinical.
[6] Deborah Pareto,et al. Brain Atrophy in Multiple Sclerosis: Clinical Relevance and Technical Aspects. , 2017, Neuroimaging clinics of North America.
[7] M. Battaglini,et al. Brain MRI atrophy quantification in MS , 2017, Neurology.
[8] M. Dwyer,et al. Brain atrophy measurements should be used to guide therapy monitoring in MS – YES , 2016, Multiple sclerosis.
[9] R. Benedict,et al. Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine , 2016, Expert review of neurotherapeutics.
[10] M. Sormani,et al. The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis , 2016, PloS one.
[11] D. Ramasamy,et al. A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients , 2016, Multiple sclerosis.
[12] A. Dibernardo,et al. The natural history of brain volume loss among patients with multiple sclerosis: A systematic literature review and meta-analysis , 2015, Journal of the Neurological Sciences.
[13] G. Tsivgoulis,et al. The effect of disease-modifying therapies on brain atrophy in patients with clinically isolated syndrome: a systematic review and meta-analysis , 2015, Therapeutic advances in neurological disorders.
[14] M. Battaglini,et al. Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis , 2015, Journal of Neurology, Neurosurgery & Psychiatry.
[15] G. Tsivgoulis,et al. The Effect of Disease Modifying Therapies on Brain Atrophy in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis , 2015, PloS one.
[16] D. Ramasamy,et al. Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome , 2014, Journal of Neurology.
[17] Olivier Gout,et al. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis , 2014, Annals of neurology.
[18] H. Wiendl,et al. Clinical Relevance of Brain Volume Measures in Multiple Sclerosis , 2014, CNS Drugs.
[19] D. Arnold,et al. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis , 2014, Annals of neurology.
[20] M. Dwyer,et al. Thalamic atrophy is associated with development of clinically definite multiple sclerosis. , 2013, Radiology.
[21] Mark Jenkinson,et al. The effect of hypointense white matter lesions on automated gray matter segmentation in multiple sclerosis , 2012, Human brain mapping.
[22] M. Battaglini,et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes , 2010, Neurology.
[23] D. Louis Collins,et al. Gradient distortions in MRI: Characterizing and correcting for their effects on SIENA-generated measures of brain volume change , 2010, NeuroImage.
[24] M. Filippi,et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis , 2008, Neurology.
[25] Rohit Bakshi,et al. The measurement and clinical relevance of brain atrophy in multiple sclerosis , 2006, The Lancet Neurology.
[26] F. Barkhof,et al. Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype. , 2002, Archives of neurology.
[27] Stephen M. Smith,et al. Accurate, Robust, and Automated Longitudinal and Cross-Sectional Brain Change Analysis , 2002, NeuroImage.
[28] Nick C Fox,et al. Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis , 2002, Journal of neurology, neurosurgery, and psychiatry.
[29] Gianpaolo Donzelli,et al. Catch-Up Growth in Short-at-Birth NICU Graduates , 2000, Hormone Research in Paediatrics.
[30] Nick C Fox,et al. Detection of ventricular enlargement in patients at the earliest clinical stage of MS , 2000, Neurology.
[31] R. Herndon,et al. A longitudinal study of brain atrophy in relapsing multiple sclerosis , 1999, Neurology.